研究業績

これまでの発表論文

2025年

  1. Nishibori S, Takeda Y, Igase M, Mizuno T.
    Engineering an Fc-inert feline IgG1 by targeted mutations: Application to anti-PD-1 antibody development.
    Vet Immunol Immunopathol. 2025 Sep 15;288:111000.

    猫のPD-1を標的としたマウス・猫キメラ抗体を遺伝子改変し、免疫細胞による不必要な影響を防ぎつつ、抗腫瘍免疫応答を得られる抗体設計を示しました。猫のがん免疫療法へ応用可能な技術です。

  2. Kato T, Okauchi N, Motegi T, Sakurai M, Maeda S, Kato D, Nakagawa T, Uchida K, Mizuno T, Igase M.
    Lactic acid regulates antitumor immunity in canine invasive urothelial carcinoma.
    PLoS One. 2025 Sep 18;20(9):e0332825.

    犬の浸潤性尿路上皮がんで、腫瘍微小環境中の乳酸が免疫を抑制しがんを進展させる役割を果たしていることを明らかにしました。この知見は、乳酸代謝を標的とした新たながん治療法の可能性を示しています。

  3. Ichimata M, Kagawa Y, Toshima A, Igase M, Mizuno T.
    Favourable Prognostic Significance of HER2 Mutations in Canine Pulmonary Adenocarcinoma Following Surgical Resection.
    Vet Comp Oncol. 2025 Sep 4. In press

    犬の肺腺癌症例を対象に、HER2遺伝子変異の有無と予後を調査しました。その結果、HER2遺伝子変異群は病勢進行が遅く、外科手術後の疾患制御が良好である可能性が示されました。

  4. Mizuno T, Kato Y, Tsukui T, Igase M.
    Characterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies.
    PLoS One. 2025 Jun 27;20(6):e0325526.
  5. Lee S, Kyaw MT, Harada K, Kusakabe KT, Igase M, Sasaki N.
    Isolation of SSEA-3-positive mesenchymal stem cells from equine bone marrow and evaluation of their pluripotency.
    Res Vet Sci. 2025 Jun; 193: 105736.
  6. Nishimori S, Okano K, Nibe K, Igase M, Mizuno T.
    A case of lingual lymphoma in a dog treated with oclacitinib.
    J Vet Med Sci. 2025 May; 87(5): 541-545.
  7. Nishibori S, Chijiwa A, Kambayashi S, Iwatani N, Sakai A, Isayama K, Mizukami Y, Shiranaga N, Mizuno T, Igase M.
    Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential.
    Res Vet Sci. 2025 May; 187: 105603.
  8. Nururrozi A, Igase M, Miyanishi K, Sakurai M, Sakai Y, Tanabe M, Mizuno T.
    Potential Contribution of Epithelial Growth Factor Receptor to PI3K/AKT Pathway Dysregulation in Canine Soft Tissue Sarcoma.
    In Vivo. 2025 Jan-Feb; 39(1): 110-119.

2024年

  1. Nururrozi A, Miyanishi K, Igase M, Sakurai M, Sakai Y, Tanabe M, Mizuno T.
    The Density of CD8+ Tumor-infiltrating Lymphocytes Correlated With Akt Activation and Ki-67 Index in Canine Soft Tissue Sarcoma.
    In Vivo. 2024 Jul-Aug; 38(4): 1698-1711.
  2. Inanaga S, Shimoda H, Igase M, Kondo H, Koizumi I, Mizuno T.
    Establishment of a histiocytic sarcoma cell line and anti-tumor effect of bortezomib in the African pygmy hedgehog (Atelerix albiventris).
    J Vet Med Sci. 2024 Aug; 86(8): 833-840.
  3. Mizuno T, Kato M, Tsukui T, Igase M.
    Development of an in vitro assay for screening programmed death receptor-1/programmed cell death ligand 1 monoclonal antibody therapy in dogs.
    Vet Immunol Immunopathol. 2024 Aug; 274: 110792.
  4. Kato T, Sakurai M, Watanabe K, Mizukami Y, Nakagawa T, Baba K, Mizuno T, Igase M.
    Identification of hypoxia-induced metabolism-associated genes in canine tumours.
    Vet Comp Oncol. 2024 Sep; 22(3): 367-376.
  5. Miyanishi K, Igase M, Murakami M, Sakai Y, Sakurai M, Tani K, Motegi T, Mizuno T.
    Establishment of a novel canine soft tissue sarcoma cell line and comparison of its characteristics with other soft tissue sarcoma cell lines.
    Res Vet Sci. 2024 May; 171: 105245.
  6. Igase M, Inanaga S, Nishibori S, Itamoto K, Sunahara H, Nemoto Y, Tani K, Horikirizono H, Nakaichi M, Baba K, Kambayashi S, Okuda M, Sakai Y, Sakurai M, Kato M, Tsukui T, Mizuno T.
    Proof-of-concept study of the caninized anti-canine programmed death 1 antibody in dogs with advanced non-oral malignant melanoma solid tumors.
    J Vet Sci. 2024 Jan; 25(1): e15.

2023年

  1. Miyanishi K, Nururrozi A, Igase M, Tanabe M, Sakurai M, Sakai Y, Shimonohara N, Murakami M, Mizuno T.
    Activation of the Akt signalling pathway as a prognostic indicator in canine soft tissue sarcoma. J Comp Pathol.
    2023 Oct; 206: 44-52.
  2. Yamamoto H, Kimura K, Horikirizono H, Tamura Y, Kambayashi S, Baba K, Okuda M, Mizuno T, Igase M.
    Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
    J Vet Med Sci. 2023 Oct; 85(10): 1047-1051.
  3. Suemura M, Miyata H, Kawamura R, Takahashi S, Igase M, Mizuno T, Ohama T, Shibutani S, Iwata H.
    Cancer-specific apoptosis induction in canine lymphoma cell lines by the endocytosis inhibitor dynasore.
    J Vet Med Sci. 2023 Aug; 85(8): 820-827.
  4. Nishibori S, Sakurai M, Kagawa Y, Uchida K, Nakagawa T, Igase M, Mizuno T.
    Cross-reactivity of anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody, clone 28-8 against feline PD-L1.
    J Vet Med Sci. 2023 Jun; 85(6): 592-600.
  5. Nishibori S, Kaneko MK, Nakagawa T, Nishigaki K, Kato Y, Igase M, Mizuno T.
    Development of anti-feline PD-1 antibody and its functional analysis.
    Sci Rep. 2023 Apr; 13: 6420.
  6. Maylina L, Kambayashi S, Baba K, Igase M, Mizuno T, Okuda M.
    Decreased sensitivity of cyclin-dependent kinase 4/6 inhibitors, palbociclib and abemaciclib to canine lymphoma cells with high p16 protein expression and low retinoblastoma protein phosphorylation.
    J Vet Med Sci. 2023 Jan; 85: 99-104.

2022年

  1. Igase M, Inanaga S, Tani K, Nakaichi M, Sakai Y, Sakurai M, Kato M, Tsukui T, Mizuno T.
    Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: A follow-up case report.
    Vet Comp Oncol. 2022 Dec; 20: 901-905.
  2. Hasegawa Y, Shosu K, Tsuji K, Shimoyama Y, Miyama TS, Baba K, Okuda M, Itamoto K, Igase M, Mizuno T.
    Intratumoral heterogeneity of c-KIT mutations in a feline splenic mast cell tumor and their functional effects on cell proliferation.
    Sci Rep. 2022 Sep; 12: 15791.
  3. Inanaga S, Igase M, Sakai Y, Hagimori K, Sunahara H, Horikirizono H, Itamoto K, Baba K, Ohsato Y, Mizuno T.
    Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs. J Vet Intern Med. 2022 Sep; 36: 1760-1769.
  4. Igase M, Iwatani N, Sakai A, Watanabe K, Mizukami Y, Mizuno T.
    The effect of 5-aminolevulinic acid on canine peripheral blood mononuclear cells.
    Vet Immunol Immunopathol. 2022 Sep; 251: 110473.
  5. Mizuno T, Inoue M, Kubo T, Iwaki Y, Kawamoto K, Itamoto K, Kambayashi S, Igase M, Baba K, Okuda M.
    Improvement of anemia in five dogs with nonregenerative anemia treated with allogeneic adipose-derived stem cells.
    Vet Anim Sci. 2022 Jul; 17: 100264.
  6. Mochizuki C, Kayabe Y, Nakamura J, Igase M, Mizuno T, Nakamura M.
    Surface Functionalization of Organosilica Nanoparticles With Au Nanoparticles Inhibits Cell Proliferation and Induces Cell Death in 4T1 Mouse Mammary Tumor Cells for DNA and Mitochondrial-Synergized Damage in Radiotherapy.
    Front Chem. 2022 May; 10: 907642.
  7. Sakai O, Yamamoto H, Igase M, Mizuno T.
    Optimization of Culture Conditions for the Generation of Canine CD20-CAR-T Cells for Adoptive Immunotherapy.
    In Vivo. 2022 Mar-Apr; 36: 764-772.

2021年

  1. Inanaga S, Igase M, Sakai Y, Tanabe M, Shimonohara N, Itamoto K, Nakaichi M, Mizuno T.
    Mismatch repair deficiency in canine neoplasms.
    Vet Pathol. 2021 Nov; 58: 1058-1063.
  2. Mizuno T, Takeda Y, Tsukui T, Igase M.
    Development of a cell line-based assay to measure the antibody-dependent cellular cytotoxicity of a canine therapeutic antibody.
    Vet Immunol Immunopathol. 2021 Oct; 240: 110315.
  3. Sakai O, Ogino S, Tsukui T, Igase M, Mizuno T.
    Development of a monoclonal antibody for the detection of anti-canine CD20 chimeric antigen receptor expression on canine CD20 chimeric antigen receptor-transduced T cells.
    J Vet Med Sci. 2021 Oct; 83: 1495-1499.
  4. Morinaga Y, Igase M, Yanase T, Sakai Y, Sakai H, Fujiwara-Igarashi A, Tsujimoto H, Okuda M, Mizuno T.
    Expression of DEP Domain-Containing 1B in Canine Lymphoma and Other Types of Canine Tumours.
    J Comp Pathol. 2021 May; 185: 55-65.

2020年

  1. Sakai O, Igase M, Mizuno T.
    Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
    Vet Comp Oncol. 2020 Dec; 18: 739-752.
  2. Igase M, Nemoto Y, Itamoto K, Tani K, Nakaichi M, Sakurai M, Sakai Y, Noguchi S, Kato M, Tsukui T, Mizuno T.
    A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
    Sci Rep. 2020 Oct; 10: 18311.
  3. Hamamura Y, Nakagawa T, Okuda M, Noguchi S, Igase M, Mizuno T.
    The inhibitory effect of canine interferon gamma on the growth of canine tumors.
    Res Vet Sci. 2020 Oct; 132: 466-473.
  4. Sakai O, Ii T, Uchida K, Igase M, Mizuno T.
    Establishment and Characterization of Monoclonal Antibody Against Canine CD8 Alpha.
    Monoclon Antib Immunodiagn Immunother. 2020 Aug; 39: 129-134.
  5. Mizuno T, Kato Y, Kaneko MK, Sakai Y, Shiga T, Kato M, Tsukui T, Takemoto H, Tokimasa A, Baba K, Nemoto Y, Sakai O, Igase M.
    Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment.
    Sci Rep. 2020 Jul; 10: 11476.
  6. Igase M, Morinaga Y, Kato M, Tsukui T, Sakai Y, Okuda M, Mizuno T.
    Establishment of rat anti-canine DEP domain containing 1B (DEPDC1B) monoclonal antibodies.
    J Vet Med Sci. 2020 Apr; 82: 483-487.
  7. Igase M, Fujiki N, Shibutani S, Sakai H, Noguchi S, Nemoto Y, Mizuno T.
    Tenovin-6 induces the SIRT-independent cell growth suppression and blocks autophagy flux in canine hemangiosarcoma cell lines.
    Exp Cell Res. 2020 Mar; 388: 111810.
  8. Kobayashi K, Baba K, Igase M, Miyama TS, Kambayashi S, Okuda M.
    Microparticle-associated tissue factor activity in dogs with disseminated intravascular coagulation.
    J Vet Med Sci. 2020 Jan; 82: 56-60.

2019年

  1. Kobayashi K, Baba K, Igase M, Primarizky H, Nemoto Y, Shimokawa Miyama T, Kambayashi S, Mizuno T, Okuda M.
    Tissue factor procoagulant activity in the tumor cell lines and plasma of dogs with various malignant tumors.
    J Vet Med Sci. 2019 Dec; 81: 1713-1721.
  2. Hwang CC, Igase M, Okuda M, Coffey M, Noguchi S, Mizuno T.
    Reovirus changes the expression of anti-apoptotic and proapoptotic proteins with the c-kit downregulation in canine mast cell tumor cell lines.
    Biochem Biophys Res Commun. 2019 Sep; 517: 233-237.
  3. Igase M, Shibutani S, Kurogouchi Y, Fujiki N, Hwang CC, Coffey M, Noguchi S, Nemoto Y, Mizuno T.
    Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma.
    Mol Ther Oncolytics. 2019 Aug; 15: 49-59.
  4. Igase M, Shousu K, Fujiki N, Sakurai M, Bonkobara M, Hwang CC, Coffey M, Noguchi S, Nemoto Y, Mizuno T.
    Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
    Vet Comp Oncol. 2019 Jun; 17: 184-193.